These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32509289)

  • 21. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
    Effingham AM
    Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
    [No Abstract]   [Full Text] [Related]  

  • 22. India: New patent law may restrict access to HIV/AIDS treatments.
    Cruess G
    HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor countries press for extension of exemption from drug patents.
    Gulland A
    BMJ; 2015 Oct; 351():h5605. PubMed ID: 26486820
    [No Abstract]   [Full Text] [Related]  

  • 24. COVID-19: Stay Cool toward Corticosteroids.
    Fujishima S
    Keio J Med; 2020 Jun; 69(2):27-29. PubMed ID: 32475851
    [No Abstract]   [Full Text] [Related]  

  • 25. The global health licensing program: a new model for humanitarian licensing at the university level.
    Roose-Snyder B; Doyle MK
    Am J Law Med; 2009; 35(2-3):281-309. PubMed ID: 19697750
    [No Abstract]   [Full Text] [Related]  

  • 26. Angiotensin II administration to COVID-19 patients is not advisable.
    Speth RC
    Crit Care; 2020 Jun; 24(1):296. PubMed ID: 32503621
    [No Abstract]   [Full Text] [Related]  

  • 27. Trade deal to curb generic-drug use.
    Maxmen A
    Nature; 2012 Sep; 489(7414):16-7. PubMed ID: 22962700
    [No Abstract]   [Full Text] [Related]  

  • 28. Engineered in India--patent law 2.0.
    Kapczynski A
    N Engl J Med; 2013 Aug; 369(6):497-9. PubMed ID: 23862973
    [No Abstract]   [Full Text] [Related]  

  • 29. Meta-analysis of Effect of Statins in Patients with COVID-19.
    Kow CS; Hasan SS
    Am J Cardiol; 2020 Nov; 134():153-155. PubMed ID: 32891399
    [No Abstract]   [Full Text] [Related]  

  • 30. [Not Available].
    Nau JY
    Rev Med Suisse; 2020 Mar; 16(685):510-511. PubMed ID: 32167254
    [No Abstract]   [Full Text] [Related]  

  • 31. COVID-19: has EBM been replaced by hype-based medicine?
    McCartney M
    Drug Ther Bull; 2020 Jul; 58(7):99-100. PubMed ID: 32451323
    [No Abstract]   [Full Text] [Related]  

  • 32. Chinese herbal experience for the 2019 novel coronavirus.
    Jiang R; Wang K; Mao W; Zhu W; Hu W; Huang L
    Crit Care; 2020 Jul; 24(1):451. PubMed ID: 32693829
    [No Abstract]   [Full Text] [Related]  

  • 33. Biologics and Small Molecules in the Treatment of COVID-19.
    Murrell DF; Rudnicka L; Shivakumar S; Kassir M; Jafferany M; Galadari H; Lotti T; Sadoughifar R; Sitkowska Z; Goldust M
    J Drugs Dermatol; 2020 Jun; 19(6):673-675. PubMed ID: 32574020
    [No Abstract]   [Full Text] [Related]  

  • 34. Balancing access to pharmaceuticals with patent rights.
    Nicol D
    Monash Bioeth Rev; 2003 Apr; 22(2):50-62. PubMed ID: 15069957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will inter partes review speed US generic drug entry?
    Darrow JJ; Beall RF; Kesselheim AS
    Nat Biotechnol; 2017 Dec; 35(12):1139-1141. PubMed ID: 29220017
    [No Abstract]   [Full Text] [Related]  

  • 36. Ensuring global access to COVID-19 vaccines.
    Yamey G; Schäferhoff M; Hatchett R; Pate M; Zhao F; McDade KK
    Lancet; 2020 May; 395(10234):1405-1406. PubMed ID: 32243778
    [No Abstract]   [Full Text] [Related]  

  • 37. Orthopaedic Considerations Following COVID-19: Lessons from the 2003 SARS Outbreak.
    Patel MS; Gutman MJ; Abboud JA
    JBJS Rev; 2020 Jul; 8(7):e2000052. PubMed ID: 32759612
    [No Abstract]   [Full Text] [Related]  

  • 38. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
    Bird RC
    J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The time for pharmaceutical compulsory licensing has expired.
    Kuhn R; Beall RF
    Nat Med; 2012 Aug; 18(8):1168. PubMed ID: 22869177
    [No Abstract]   [Full Text] [Related]  

  • 40. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.